|
Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer.〔(Statement On A Nonproprietary Name Adopted By The Usan Council - Mapatumumab ), ''American Medical Association''.〕 This drug was discovered by Cambridge Antibody Technology (CAT) and Human Genome Sciences, Inc. (HGS) as a result of the collaboration between the two companies in 1999 in exploitation CAT's phage display technology. Early work by CAT and HGS indicated that mapatumumab induced cell death in multiple tumour types both in vitro and in vivo. == Clinical trials == A phase 1 clinical trial in 2004 demonstrated the safety and tolerability of mapatumumab in cancer patients with advanced solid tumors or non-Hodgkin’s lymphoma, and supported further evaluation in phase 2 clinical trials, both as a single agent and in combination with chemotherapy.〔(【引用サイトリンク】title=Human Genome Sciences reports results of ongoing phase 1 clinical trials of HGS-ETR1 in patients with advanced cancers )〕 2005: In a phase 2 clinical trial mapatumumab was well tolerated and could be administered safely in patients with advanced non-small-cell lung cancer (NSCLC) and advanced colorectal cancer. Stable disease was observed in a number of NSCLC patients.〔(【引用サイトリンク】title=Human Genome Sciences reports results of phase 2 clinical trial of HGS-ETR1 in patients with non-small-cell lung cancer )〕〔(【引用サイトリンク】title=Human Genome Sciences reports results of phase 2 clinical trial of HGS-ETR1 in patients with advanced colorectal cancer )〕 In two phase 1b clinical trials mapatumumab in combination with chemotherapy was well tolerated by patients with advanced solid tumors. Partial response was observed in a number of patients in each of the studies.〔(【引用サイトリンク】title=Human Genome Sciences reports interim results of phase 1B clinical trials of HGS-ETR1 in combination with chemotherapy in patients with advanced solid tumors )〕 The results of a phase 2 clinical trial demonstrated that mapatumumab was well tolerated and capable of producing clinical responses when administered as monotherapy in patients with advanced non-Hodgkin’s lymphoma, according to HGS.〔(【引用サイトリンク】title=Human Genome Sciences reports results of phase 2 clinical trial of HGS-ETR1 in patients with advanced non-Hodgkin’s lymphoma )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Mapatumumab」の詳細全文を読む スポンサード リンク
|